Real-World Assessment of the Xpert MTB/XDR for Detecting Isoniazid and Second-Line Drug Resistance Among TB Patients
International Journal of Molecular Sciences · 12.03.2026 · 27 (6) · 2597
DOI: 10.3390/ijms27062597 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 12.03.2026. Verfasst von Andrei Makhon und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Public Health Laboratory, Public Health Directorate, Ministry of Health, Tel Aviv 6810416, Israel. Hauptthemen laut MEDLINE: Isoniazid, Mycobacterium tuberculosis, Antitubercular Agents, Extensively Drug-Resistant Tuberculosis. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Israeli Ministry of Health.
Abstract (Originalsprache)
Rapid and accurate detection of drug-resistant tuberculosis (DR-TB) is critical for effective treatment and containment. The Xpert® MTB/XDR (GXXDR) assay is designed to detect Mycobacterium tuberculosis complex (MTBC) and resistance to isoniazid and second-line anti-TB drugs directly from clinical specimens. We evaluated the clinical performance of GXXDR using 61 MTBC-positive specimens with available phenotypic drug susceptibility testing results. GXXDR results were compared to a phenotypic drug susceptibility test (pDST) and whole-genome sequencing (WGS) to assess sensitivity, specificity, and concordance. Resistance to isoniazid, fluoroquinolones, amikacin, capreomycin, and ethionamide was analyzed. Sensitivity comparisons between GXXDR, WGS, pDST, and manufacturer data were performed using Fisher’s exact and Tango tests. GXXDR demonstrated a high specificity for most drugs and a strong sensitivity for isoniazid (93.8%) and fluoroquinolone (92.3%), consistent with manufacturer reports. In contrast, the sensitivity for amikacin (58.3%), capreomycin (35.7%), and ethionamide (27.3%) was significantly lower than stated by the manufacturer (91.9%, 84.0% and 64.7%, respectively), likely due to resistance mutations outside the assay’s target regions. Sensitivity concordance of GXXDR with WGS was high for all drugs, except ethionamide. The GXXDR assay enables rapid and reliable detection of isoniazid and fluoroquinolone resistance in clinical settings, though sensitivity for certain second-line drugs may be affected by regional genetic diversity. These findings underscore the importance of integrating local epidemiological data to optimize molecular diagnostics for DR-TB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Public Health Laboratory, Public Health Directorate, Ministry of Health, Tel Aviv 6810416, Israel.
- Clalit Health Services, Regional Laboratory of Haifa and Western Galilee, Nesher 3688847, Israel.
ORCID-Profile: Zeev Dveyrin, Noa Tejman-Yarden
Förderung
- Israeli Ministry of Health
Zitieren
APA
Makhon, A., Fuchs, S., Rubinstein, M., Brodsky, M., Dveyrin, Z., Tejman-Yarden, N., & Losev, Y. (2026). Real-World Assessment of the Xpert MTB/XDR for Detecting Isoniazid and Second-Line Drug Resistance Among TB Patients. International Journal of Molecular Sciences, 27(6), 2597. https://doi.org/10.3390/ijms27062597
Vancouver
Makhon A, Fuchs S, Rubinstein M, Brodsky M, Dveyrin Z, Tejman-Yarden N, et al. Real-World Assessment of the Xpert MTB/XDR for Detecting Isoniazid and Second-Line Drug Resistance Among TB Patients. International Journal of Molecular Sciences. 2026;27(6):2597. doi:10.3390/ijms27062597
BibTeX
@article{Makhon2026,
author = {Makhon, Andrei and Fuchs, Sivan and Rubinstein, Mor and Brodsky, Maya and Dveyrin, Zeev and Tejman-Yarden, Noa and Losev, Yelena},
title = {Real-World Assessment of the Xpert MTB/XDR for Detecting Isoniazid and Second-Line Drug Resistance Among TB Patients},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {6},
pages = {2597},
doi = {10.3390/ijms27062597}
}
EUVIMED